Examining the Efficacy of Toceranib Phosphate (Palladia) as a Primary and/or Adjuvant Agent in the Treatment of Canine Nasal Carcinoma

12/28/2011
Non-randomized study examining the efficacy of toceranib alone or radiation therapy plus toceranib. The financial incentive includes toceranib and follow-up rechecks depending on the study arm the patient is in.

Dogs with confirmed diagnosis of nasal carcinoma will receive Palladia every other day and depending on client preference, will also receive radiation therapy (10 daily treatments over two weeks). Recheck exams will be performed at 1, 2, and 4 weeks after initiating Palladia, and then every 4 weeks thereafter for a total of 1 year. For those dogs that receive radiation therapy, a CT scan will be repeated at 3, 6, and 12 months following radiation treatment. For those dogs that do not receive radiation therapy, a CT scan will be performed at 3 months following therapy only.